Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big pharma joins UK government in Alzheimer's research funding boost

This article was originally published in Scrip

Executive Summary

Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly and Pfizer have all committed in principle to investing, alongside the charity Alzheimer's Research UK and the UK government, in a $100m Dementia Discovery Fund announced by the UK health secretary Jeremy Hunt at the World Health Organization’s First Ministerial Conference on Global Action Against Dementia on 17 March. The UK government has been working with JP Morgan to structure the Dementia Discovery Fund as an innovative method for financing dementia research. It will be structured as a typical venture capital fund, but will be the first to focus solely on dementia research. The idea is to bring together the combined expertise of government, financial, industry and charity partners to develop pioneering new drugs to treat the condition. The money committed by investors includes the £15m that the UK government announced for the fund in autumn 2014, plus $25m (about £17m) from GlaxoSmithKline, $10m from Johnson & Johnson and further undisclosed commitments from the other companies. There will be an opportunity for additional interested investors to participate in the fund at a later stage.

You may also be interested in...



Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m

Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.

AZ’s Fasenra Joins GSK’s Nucala In Nasal Polyp Pursuit Of Sanofi’s Dupixent

Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.

DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front

A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel